Thirty years after a monumental shift in how science understands the human body, the pioneering researcher behind blockbuster medications like Mounjaro and Zepbound is looking ahead to the next frontier. Professor Matthias Tschöp, a leading figure in metabolic research, recently shared a comprehensive look at three decades of scientific discovery—tracing a path from early laboratory experiments on obese mice to the development of some of the most widely discussed pharmaceutical treatments in modern medicine.
In a recent podcast interview, Tschöp detailed how his team’s relentless pursuit of better treatments has led them far beyond current mono, dual, and triple agonists. His newest designs promise even stronger physiological results while minimizing the adverse side effects that frequently plague patients. Ranging from the potential of a quintuple agonist to the surprising anatomical regions where these medications actually exert their influence, Tschöp’s insights offer a rare glimpse into the future of personalized medicine and the ongoing evolution of pharmacological treatments for metabolic health.
The Quintuple Agonist: What Comes After Retatrutide
The landscape of weight-loss pharmacology is moving at a blistering pace. Tschöp anticipates that retatrutide—a triple agonist currently navigating the final stages of clinical development—will likely secure regulatory approval around the end of this year or early next year. Clinical data indicates that retatrutide achieves weight-loss efficacy nearing 30 percent, putting a weekly injectable medication on par with the dramatic results historically reserved for invasive surgical interventions like gastric bypass, yet achieving this without introducing a broader profile of side effects.
However, Tschöp and his research colleagues did not pause their investigations upon completing retatrutide. Just a few months ago, his team published a landmark paper in the scientific journal Nature detailing a new pharmaceutical candidate: a quintuple agonist. This advanced molecular design pairs traditional GIP and GLP-1 mechanisms with a triple PPAR agonist. To deliver these complex compounds effectively, the researchers utilized specialized peptides designed to ferry small-molecule payloads directly into targeted cellular destinations, operating much like a biological Trojan horse.
Looking forward, Tschöp envisions a future of personalized metabolic medicine where physicians can utilize these multi-signal drugs to target select organs precisely, simultaneously addressing localized inflammation and recalibrating the body’s baseline calorie-burning mechanisms.
A GLP-1-Free Drug With No Nausea?
Despite the unprecedented success of current medications, gastrointestinal discomfort remains the single most common complaint among patients. Symptoms such as nausea, vomiting, diarrhea, and constipation affect a significant percentage of individuals beginning treatment, which is precisely why physicians must titrate dosages upward at a slow and cautious pace over several weeks or months.
Because mono, dual, and triple agonists all incorporate a GLP-1 receptor component, Tschöp suspected that this specific biological signal might be the primary driver of digestive distress. This suspicion prompted a bold scientific question: What if researchers could engineer a therapeutically effective version that is entirely free of GLP-1?
To test this hypothesis, his team engineered a GIP-glucagon dual agonist. According to Tschöp, preclinical trials involving mice, rats, and monkeys demonstrated that this novel formulation successfully cut body weight by margins comparable to retatrutide, all without triggering elevations in blood glucose or causing any observable gastrointestinal side effects in the animal subjects. Human clinical trials are eagerly hoped for as early as next year.
Nevertheless, Tschöp is quick to emphasize that animal data represents only the foundational first step in drug development. He repeatedly notes that human physiology differs significantly from rodent models, meaning that rigorous clinical trial results in human populations will ultimately decide whether this promising profile holds true in practice.
Why Obesity Is a Brain Disease
Tschöp’s journey into the intricacies of metabolism began back in 1994, when researcher Jeffrey Friedman published a landmark discovery in Nature regarding leptin, revealing that fat tissue functions as an active endocrine organ rather than a passive energy storage depot. Inspired by these findings, Tschöp transitioned away from clinical medicine to immerse himself entirely in the emerging field of metabolic research.
This era of rapid discovery continued with the identification of ghrelin, commonly known as the hunger hormone, in the year 2000. Because both leptin and ghrelin exert their primary physiological effects within the central nervous system, and because human genetic studies pointed strongly toward central nervous system regulation, the scientific consensus began to shift fundamentally.
In Tschöp’s view, the accumulated evidence made it clear that scientific reality dictated obesity was fundamentally a brain disease. Consequently, if researchers wanted to develop effective treatments for excess body weight, they would need to find safe and effective ways to target the brain.
Directly targeting central nervous system pathways, however, proved historically difficult and fraught with risk. Early attempts to utilize cannabinoid receptor blockers successfully curbed patient appetite, but the treatments were accompanied by severe psychiatric and cardiovascular side effects, including clinical depression. Tschöp and his colleagues realized that a safer workaround involved utilizing Mother Nature’s own toolkit—specifically leveraging naturally occurring gut hormones that already communicate routinely with the brain without inducing toxic central nervous system reactions.
The Surprise: Nobody Fully Knows How These Drugs Work
Despite the massive commercial success and widespread clinical adoption of these medications, Tschöp acknowledges a humbling reality that highlights how much remains to be discovered in basic science. There is still a tremendous amount researchers do not fully understand, including the precise mechanisms by which these drugs achieve their profound metabolic effects.
For decades, the prevailing scientific focus centered squarely on the hypothalamus, the region of the brain where leptin was historically known to act. However, emerging research reveals that modern incretin-based medications actually exert a substantial portion of their influence in the hindbrain—an entirely different anatomical region of the central nervous system.
This revelation means that much of what researchers long believed about the precise neurobiology of body-weight control is disconnected from the actual mechanisms driving the success of these medications. Tschöp characterizes this disconnect as a profound lesson in scientific serendipity, proving that sometimes therapies can succeed clinically long before researchers fully map every underlying pathway.
Not the "Everything Drugs"
While popular media headlines frequently characterize modern weight-loss medications as miraculous cures for virtually every modern ailment, Tschöp pushes back firmly against such sweeping claims. In his professional estimation, they are definitively not universal cures.
He maintains that the improvements in cardiovascular health, cancer risk reduction, and neurodegeneration observed in patients are largely downstream benefits that flow naturally from improved systemic metabolism and reduced overall body weight. However, direct pharmacological effects do appear to play a role in altering addictive behaviors.
Sharing a personal perspective on how the drugs alter daily cognitive patterns, Tschöp noted the profound relief reported by patients whose constant, intrusive thoughts about food quiet down significantly. Clinical reports have increasingly extended these behavioral shifts to encompass other compulsive urges, including alcohol consumption, nicotine use, and gambling. Tschöp stresses, however, that long-term prospective clinical studies evaluating these behavioral impacts are still missing, meaning current evidence remains preliminary.
When considering whether these medications dull an individual’s overall capacity for pleasure, Tschöp notes that clinical data reveals no depression signal; patients continue to enjoy their meals, but experience a natural satiety that allows them to simply skip a second helping.
Muscle Loss: Real, But Not Drug-Specific
Addressing a frequent concern among patients and clinicians regarding lean mass reduction during treatment, Tschöp explains that any form of significant weight loss—whether achieved through traditional caloric restriction diets or modern pharmaceutical intervention—strips away a combination of fat and lean tissue. Skeletal muscle fundamentally lacks the specific biological receptors targeted by these medications.
Tschöp uses a straightforward analogy to explain the physiological process: shedding twenty kilograms of excess fat is biologically comparable to dropping a heavy backpack, meaning the body simply requires less muscle mass to carry a lighter frame. However, he acknowledges that older adults face a different set of physiological constraints. At age 59, Tschöp agrees that rebuilding or maintaining muscle mass becomes progressively more challenging with advancing age, making the trade-off particularly steep for individuals who are not significantly overweight.
While researchers are actively developing muscle-building pharmaceutical add-ons to counteract this effect, Tschöp urges caution against excessive optimism. Efforts to utilize myostatin inhibitors to preserve lean mass introduce significant biological complications, noting that the human heart is also a muscle, and raising questions about the safety of stimulating unrestricted muscular growth.
Microdosing and the Peptide Black Market
The prospect of microdosing these medications to benefit individuals who do not clinical qualify as obese is, in Tschöp’s view, a plausible concept. He notes that clinical data indicates losing just three to five percent of total body weight can yield measurable improvements in cardiovascular and metabolic health parameters.
Nevertheless, he emphasizes that robust clinical trials evaluating microdosing strategies do not yet exist. Because these approaches must be studied carefully within controlled environments, he explicitly advises against attempting such regimens at home.
Of greater immediate concern to the researcher is the burgeoning online black market for peptides. Retatrutide and related compounds are already circulating widely through unregulated online catalogs, raising serious safety concerns—particularly regarding the potential misuse of these potent metabolic drugs by vulnerable populations, such as individuals suffering from anorexia nervosa.
Tschöp also cautions against generalized hype surrounding peptides as a class of molecules, pointing out that while many beneficial therapeutics are peptides, some of the most lethal mushroom poisons in nature are also peptides. The molecular structure alone does not inherently make a substance good or bad.
Over time, broader economic factors may help alleviate illicit demand. Tschöp estimates that the actual chemical synthesis costs for these compounds run under ten dollars per month, suggesting that increased market competition and eventual patent expirations will inevitably drive down retail prices.
Why Stopping Means the Weight Returns
To understand why patients frequently regain weight after discontinuing therapy, Tschöp draws a parallel to standard treatments for chronic conditions like hypertension. If a patient stops taking a prescribed beta blocker, their blood pressure inevitably climbs back up to baseline levels.
The disease simply returns once the treatment is removed, a phenomenon that occurs across the vast majority of chronic medical conditions. Interestingly, clinical data shows that weight rebound following the cessation of incretin therapies often arrives more slowly than predictive models initially suggested. This delayed return may be partially attributed to active lifestyle habits that patients successfully form while undergoing treatment. Additionally, adaptive thermogenesis remains a measurable biological factor, as the body naturally burns fewer calories following significant weight loss due to metabolic slowdown.
Individual patient responses also vary widely. Tschöp notes that some individuals carry naturally weaker GIP receptors, leading him to predict that genetic screening will eventually play a vital role in matching individual patients with the precise pharmaceutical combinations best suited to their unique biology.
How the Inventor Lives
Reflecting on the personal side of his decades-long immersion in metabolism research, Tschöp admits that experiencing these medications firsthand offered a unique perspective. During an Italian family vacation, he decided to test a dual agonist personally. The effects were immediate and unmistakable: traditional local delicacies like tiramisu lost their appeal, pasta portion sizes naturally shrank, and an evening gin and tonic failed to tempt him.
Two weeks into the experiment, his brother-in-law delivered a lighthearted verdict on the behavioral shift: "You used to be more fun."
Having observed the profound appetite-suppressing power of the compounds he helped discover, Tschöp is now considering exploring a microdosing regimen for himself, balancing the scientific pursuit of metabolic health with the simple joys of everyday life.
